Cargando…

Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment

Pembrolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It is an FDA-approved immunotherapy used to treat various malignancies. With its wide use in cancer therapy, there are many known side effects. It is a common cause of endocrinopathies such as thyroid disease an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zilberman, Stephanie, Rafii, Daniel C, Giunta, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374333/
https://www.ncbi.nlm.nih.gov/pubmed/37519548
http://dx.doi.org/10.7759/cureus.41049

Ejemplares similares